OIM
Oracle Investment Management Portfolio holdings
AUM
$116M
This Quarter Return
+5.25%
1 Year Return
+84.31%
3 Year Return
+539.5%
5 Year Return
+791.07%
10 Year Return
+13,222.09%
AUM
$154M
AUM Growth
+$154M
(+3.1%)
Cap. Flow
+$3.81M
Cap. Flow
% of AUM
2.48%
Top 10 Holdings %
Top 10 Hldgs %
99.79%
Holding
20
New
2
Increased
3
Reduced
2
Closed
4
Top Buys
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$12.2M |
| 2 |
Teladoc Health
TDOC
|
$4.5M |
| 3 |
Ardelyx
ARDX
|
$1.55M |
| 4 |
Recursion Pharmaceuticals
RXRX
|
$635K |
| 5 |
Palantir
PLTR
|
$84.4K |
Top Sells
| 1 |
GeneDx Holdings
WGS
|
$4.74M |
| 2 |
Biohaven
BHVN
|
$4.47M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$4.03M |
| 4 |
Phathom Pharmaceuticals
PHAT
|
$1.18M |
| 5 |
Pacific Biosciences
PACB
|
$512K |
Sector Composition
| 1 | Healthcare | 97.33% |
| 2 | Technology | 1.62% |
| 3 | Consumer Discretionary | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
GeneDx Holdings
WGS
$3.72B
| $85.9M | 43.34% | 969,954 -53,514 | -5% | -$4.74M |
|
|
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
| $23.4M | 11.83% | 531,351 +276,578 | +109% | +$12.2M |
|
|
3
Biohaven
BHVN
$1.63B
| $16M | 8.08% | 665,945 -185,825 | -22% | -$4.47M |
|
|
4
Ardelyx
ARDX
$1.53B
| $11.8M | 5.96% | 2,404,438 +315,007 | +15% | +$1.55M |
|
|
5
Teladoc Health
TDOC
$1.37B
| $4.5M | 2.27% | +565,900 | New | +$4.5M |
|
6
QuidelOrtho
QDEL
$1.95B
| $4.14M | 2.09% | 118,291 | – | – |
|
7
Forian
FORA
$61.3M
| $2.73M | 1.38% | 1,366,107 | – | – |
|
|
8
Palantir
PLTR
$372B
| $2.49M | 1.26% | 29,500 +1,000 | +4% | +$84.4K |
|
9
CAVA Group
CAVA
$7.83B
| $1.61M | 0.81% | 18,600 | – | – |
|
|
10
Recursion Pharmaceuticals
RXRX
$2.04B
| $635K | 0.32% | +120,000 | New | +$635K |
|
11
Biogen
BIIB
$19.4B
| $330K | 0.17% | 2,412 | – | – |
|
|
12
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – | -535,558 | Closed | -$4.03M |
|
13
EyePoint Pharmaceuticals
EYPT
$797M
| – | – | -32,500 | Closed | -$242K |
|
14
Novavax
NVAX
$1.21B
| – | – | 0 | – | – |
|
|
15
Pacific Biosciences
PACB
$393M
| – | – | -279,638 | Closed | -$512K |
|
|
16
Phathom Pharmaceuticals
PHAT
$864M
| – | – | -145,064 | Closed | -$1.18M |
|
17
Peloton Interactive
PTON
$3.1B
| – | – | 0 | – | – |
|
18
Viking Therapeutics
VKTX
$3.04B
| – | – | 0 | – | – |
|
19
Health Care Select Sector SPDR Fund
XLV
$33.9B
| – | – | 0 | – | – |
|
20
SPDR NYSE Technology ETF
XNTK
$1.25B
| – | – | 0 | – | – |
|